Gilead Presents Real- World and Long- Term Data From HIV Research Programs at HIV Glasgow 2022
New Clinical and Case- Reported issues in People with HIV on Biktarvy ® in Observational BICSTaR Study Demonstrate harmonious Efficacy Profile in Real- World Setting –
– Long- Term Switch Data farther Establish the Robust and Durable Efficacy Profile of Biktarvy –
– Clinical Data Reinforces the Sustained efficacity of doubly-Monthly Lenacapavir in People withMulti-Drug Resistant HIV –
Gilead lores,Inc.( Nasdaq GILD) moment blazoned the company’s forthcoming new data from its HIV exploration and development programs to be presented at the 30th International Congress on Drug Therapy in HIV Infection( HIV Glasgow 2022) in Glasgow, Scotland and nearly from October 23- 26, 2022. Gilead will present data supporting its current and channel inventions in HIV treatment and the rearmost exploration from its ongoing cure development program, reflecting the company’s innovative approach to nonstop scientific discovery.
“ Continued scientific invention and inclusive approaches are essential in the discovery and development of person- centred options that address the evolving requirements of a broad range of individualities and communities affected by HIV, ” said Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead lores. “ The data presented at HIV Glasgow reflect the rearmost progress in our exploration and development programs and emphasize Gilead’s commitment to driving transformational invention in HIV exploration. Our thing, together with the broader HIV community, is to end the HIV epidemic for everyone, far and wide. We look forward to connecting in person in Scotland at this time’s meeting and participating these data with the scientific community as we work towards this important thing. ”
Lenacapavir is a first- in- class, long- acting HIV capsid asset approved in the EU and UK for the treatment of HIV infection, in combination with other antiretroviral( s), in grown-ups withmulti-drug resistant HIV infection for whom it’s else not possible to construct a suppressiveanti-viral authority. Lenacapavir, alone or in combination, isn’t approved by any nonsupervisory authority outside of the EU or the UK for any use. The European Marketing Authorization applies to all 27 member countries of the European Union, as well as Norway, Iceland and Liechtenstein.
For important safety information for lenacapavir, including dosing and system of administration, special warnings, medicine relations and adverse medicine responses, please see the Summary of Product Characteristics( SmPC) for lenacapavir, available from the European Medicines Agency website atwww.ema.europa.eu.
There’s presently no cure for HIV or AIDS.
suggestion for Biktarvy
Biktarvy is indicated as a complete authority for the treatment of mortal immunodeficiency contagion type 1( HIV- 1) infection in grown-ups and pediatric cases importing at least 14 kg who have no antiretroviral treatment history or to replace the current antiretroviral authority in those who are virologically- suppressed( HIV- 1 RNA lower than 50 clones per mL) on a stable antiretroviral authority with no history of treatment failure and no given negotiations associated with resistance to the individual factors of Biktarvy.
Biktarvy is a complete HIV treatment that combines three important drugs to form the lowest 3- medicine, integrase beachfront transfer asset( INSTI)- grounded single- tablet authority( STR) available, offering simple once- diurnal dosing with or without food, with a limited medicine commerce eventuality and a high hedge to resistance. Biktarvy combines the novel, unboosted INSTI bictegravir, with the Descovy ®( emtricitabine 200 mg/ tenofovir alafenamide 25 mg tablets, F/ TAF) backbone. Biktarvy is a complete STR and shouldn’t be taken with other HIV drugs.
Sunlenca is a first- in- class, long- acting HIV capsid asset approved in the European Union for the treatment of HIV infection, in combination with other antiretroviral( s), in people withmulti-drug resistant HIV who are heavily- treatment educated. Sunlenca’smulti-stage medium of action is distinguishable from other presently approved classes of antiviral agents and is designed to give a new avenue for the development of a long- amusement treatment option for individualities withmulti-drug resistant HIV whose contagion was no longer effectively responding to remedy. While utmost antivirals act on just one stage of viral replication, Sunlenca is designed to inhibit HIV at multiple stages of its lifecycle and has no known cross resistance to other being medicine classes. Sunlenca is the only HIV treatment option administered doubly- yearly.
About Gilead lores
Gilead lores,Inc. is a biopharmaceutical company that has pursued and achieved improvements in drug for further than three decades, with the thing of creating a healthier world for all people. The company is committed to advancing innovative drugs to help and treat life- hanging conditions, including HIV, viral hepatitis and cancer.
For 35 times, Gilead has been a leading inventor in the field of HIV, driving advances in treatment, forestallment and cure exploration. Gilead experimenters have developed 12 HIV specifics, including the first single- tablet authority to treat HIV, the first antiretroviral forpre-exposure prophylaxis( PrEP) to reduce the threat of acquiring HIV infection, and the first, long- acting injectable HIV treatment drug administered doubly- yearly. Our advances in medical exploration have helped to transfigure HIV into a preventable, habitual condition for millions of people.
Gilead is committed to continued scientific invention to give results for the evolving requirements of people affected by HIV around the world. Through hookups and collaborations, the company also aims to ameliorate education, expand access and address walls to watch, with the thing of ending the HIV epidemic for everyone, far and wide. Gilead was honored as the number one humanitarian funder of HIV- related programs in a report released by Funders Concerned About AIDS.
Gilead operates in further than 35 countries worldwide, with headquarters in Foster City, California.